Biotechnology

Strategic Collaboration | Sanyou Bio and NovoCodex Partner to Co-Develop Innovative Dual-Payload ADCs

SHANGHAI and SHAOXING, China, Sept. 24, 2026 /PRNewswire/ -- Sanyou Biopharmaceuticals Co., Ltd. ("Sanyou Bio") and NovoCodex Biopharmaceuticals Co., Ltd. ("NovoCodex") jointlyannounced that the two companies have formally entered into a strategic collaboration agreement. The partnership will foc...

2026-09-24 22:00 4133

Windsor Capital Completes $50 Million Strategic Investment in Space Labs

Investment for a 4.9% minority stake implies an approximately $1 billion post-money valuation for the Slovenian technology company. HONG KONG and LJUBLJANA, Slovenia, Sept. 24, 2026 /PRNewswire/ -- Windsor Capital today announced the completion of a $50 million strategic investment in Space Labs...

2026-09-24 21:09 2680

Earendil Labs Announces Research Collaboration with Genentech to Discover and Develop Therapeutic Bispecific Antibodies in Oncology

WILMINGTON, Del., Sept. 24, 2026 /PRNewswire/ -- Earendil Labs, an AI-powered biotechnology company advancing next-generation biologics, today announced a research collaboration with Genentech, a member of the Roche Group, to discover and develop multiple therapeutic bispecific antibody programs ...

2026-09-24 19:00 1892

Daewoong Pharmaceutical Presents Baseline Characteristics of 104 Patients in Global Phase 2 Trial for IPF Drug Candidate 'Bersiporocin' at ERS 2026

* 104 IPF patients enrolled in US and South Korea as global Phase 2 trial progresses toward completion * Study includes both antifibrotic-treated and untreated patients; top-line data expected in H1 2027 * First-in-class PRS inhibitor being developed as a potential new therapeutic option...

2026-09-24 08:00 2695

Werfen Announces US FDA 510(k) Clearance and CE Mark for Aptiva® Antiphospholipid Syndrome IgA Reagent

FDA Clearance and CE Mark Complete Aptiva's Antiphospholipid Syndrome Portfolio, Expanding Global Access to Comprehensive APS Testing SAN DIEGO, Sept. 23, 2026 /PRNewswire/ -- Werfen today announced that its Aptiva Antiphospholipid Syndrome (APS) Immunoglobulin A (IgA) Reagent has received both ...

2026-09-23 20:00 1507

Angel Yeast's Angeopro™ Yeast Protein Achieves Dual International Certifications

Setting a New Standard in High-Quality Nutrition SHANGHAI, Sept. 23, 2026 /PRNewswire/ -- Angeopro™ Yeast Protein range F80, F84, Hi90-A, and S80-A, developed byAngel Yeast (SSE: 600298), recently receivedMonash University Low FODMAP CertifiedTM

2026-09-23 19:13 1823

HKSH Medical Group and United Imaging Mark Launch of Hong Kong's First Long-Axial PET/CT

HONG KONG, Sept. 23, 2026 /PRNewswire/ -- HKSH Medical Group (HKSH) and United Imaging Healthcare (United Imaging) announced on September 23 the arrival of Hong Kong's first long-axial PET/CT, the uMI Panorama GS, at HKSH Cancer Centre, providing a new technology platform for molecular imaging cl...

2026-09-23 18:30 1204

Innovent to Present New Clinical Data of Next-gen IO and ADC Pipeline at the 2026 ESMO Annual Meeting

SAN FRANCISCO and SUZHOU, China, Sept. 23, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmun...

2026-09-23 16:48 1551

Caliway Announces Positive Phase 2 Results of CBL-514 in Dercum's Disease, Achieving Primary Endpoint with Statistically Significant and Sustained Pain Reduction

* Primary Endpoint Achieved in CBL-0202DD Phase 2 Trial—CBL-514 delivered statistically significant pain reduction across both FAS and PP populations compared with placebo. * Expansion Opportunity Beyond Dercum's Disease—Study findings support the potential development of CBL-514 for Lipedema...

2026-09-23 10:08 1409

Novo receives Singapore approval for Wegovy® as first treatment for MASH with liver fibrosis

ESSENCE trial data showed 63% of participants receiving semaglutide achieved steatohepatitis resolution without worsening of liver fibrosis, compared with 34% receiving placebo, at Week 72. * Singapore's Health Sciences Authority (HSA) has approved Wegovy® (once-weekly injectable semaglutide 2...

2026-09-23 10:05 2984

Mayo Clinic Laboratories Invests in Pathology Asia Holdings and LifeStrands Genomics to Advance Diagnostics and Precision Medicine

SINGAPORE, Sept. 23, 2026 /PRNewswire/ -- Mayo Clinic Laboratories  and Pathology Asia Holdings  (PAH) have announced a strategic investment and collaboration aimed at expanding access to advanced diagnostics and precisio...

2026-09-23 09:30 986

XtalPi AI Enables Seven-Month PCC Nomination for Viva-Thera's MPER-Targeting HIV-1 Program

* Viva-Thera makes its public debut with four modalities pursuing HIV prevention, treatment and cure, supported by XtalPi's platform capabilities. * Viva-Thera combines its first atomic-resolution MPER-TMD-CT structure with XtalPi's AI and automation platform to advance a small-molecule PCC. ...

2026-09-23 01:36 924

Tsingke Enables High-Throughput Validation of AI-Designed Proteins and Antibodies

BEIJING, Sept. 22, 2026 /PRNewswire/ -- Tsingke today announced an integrated high-throughput validation workflow designed to help researchers experimentally evaluate large libraries of AI-designed proteins and antibodies. Combining gene synthesis, parallel expression, high-throughput screening, ...

2026-09-22 22:22 807

Bio-Techne Opens New Customer Experience Center in Düsseldorf to Accelerate Scientific Discovery and Customer Collaboration

* New flagship facility provides hands-on access to Bio-Techne technologies, workflows and scientific expertise * Regional hub will support researchers and organizations across the DACH and broader EMEA regions * Center strengthens collaboration, training and innovation within Europe's life...

2026-09-22 21:00 2468

Angel Yeast Explores a New Approach to Salt Reduction Without Compromising Flavor

BEIJING, Sept. 22, 2026 /PRNewswire/ -- At the 2026 Food Science Salt Reduction Technology Symposium held recently in Beijing,Angel Yeast (SSE: 600298) joined more than 200 experts and representatives from academia and industry to discuss salt-reduction technologies, ...

2026-09-22 20:54 1058

Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders

Clinical Milestone Expands Development of Paxalisib Beyond Oncology and Triggers $2 Million Payment to Kazia SYDNEY, Sept. 22, 2026 /PRNewswire/ -- Kazia Therapeutics Limited

2026-09-22 19:30 2200

Multiple Sacituzumab Tirumotecan (sac-TMT) Studies Selected as LBAs at ESMO 2026, OptiTROP-Lung04 and OptiTROP-Lung06 to be Presented in the Lung Cancer Session

CHENGDU, China, Sept. 22, 2026 /PRNewswire/ -- The 2026 European Society for Medical Oncology (ESMO) Congress will be held in Madrid, Spain, from October 23 to 27. Multiple Phase III clinical studies of the TROP2 ADC sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) (佳泰莱®) developed...

2026-09-22 15:48 1523

BoomRay Enters Exclusive Global License Agreement with Novartis for a Novel Radioligand Therapy Asset

SUZHOU, China, Sept. 22, 2026 /PRNewswire/ -- Boomray Pharmaceuticals Co., Ltd. ("BoomRay"), a clinical-stage biotechnology company pioneering innovative radioligand therapies (RLTs) for precision oncology diagnostics and therapeutics, today announced that it has entered into an exclusive global ...

2026-09-22 12:00 2025

Bestzyme Launches World's First Dedicated, Automated Smart Production Line for Sweet Proteins in Jinan

JINAN, China, Sept. 21, 2026 /PRNewswire/ -- Bestzyme, a synthetic biology company under GenScript Biotech, today announced the completion of the world's first dedicated, automated smart production line for sweet proteins at its Jinan facility. This milestone marks the first full-chain integratio...

2026-09-22 10:30 2181

Ivonescimab First-Line Biliary Tract Cancer Phase III Overall Survival Data Selected as ESMO Late-Breaking Abstract; Nearly 30 Akeso Studies to Be Presented at ESMO 2026

HONG KONG, Sept. 21, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company")announced that nearly 30 clinical studies of its globally first-in-class bispecific antibodies will be presented at the 2026 European Society for Medical Oncology (ESMO) Congress, taking place October 23–27 ...

2026-09-22 07:46 2096
1234567 ... 356